Acceleron Pharma Inc. XLRN
178.75 0.00 (+0.00%)
Apr 24, 2025, 3:47 PM EDT
177.20 Day range 179.85
52-week range unavailable
- Market cap
- 10.93B
- Forward P/E
- -54.17
- Volume
- 7.88M
- Open
- 179.85
- Previous close
- 178.75
- Day's range
- 177.20 – 179.85
- Analysts
- Buy
- Price target
- 178.88 (+0.1%)
- Earnings date
- Nov 4, 2021
6M +5.02 (+2.89%)
Key statistics
- Price / sales
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 169.49
- 200-day average
- 137.95
Analyst view
Consensus: buy
Buy
Price target (mean) 178.88 +0.1% upside
Now 178.75
- Target (low)
- 171.00
- Target (mean)
- 178.88
- Target (high)
- 180.00
Ratings (0m) 15 11 buy · 3 hold · 1 sell
- Strong buy3
- Buy8
- Hold3
- Sell1
- Strong sell0
Next earnings
Nov 4, 2021
Expected Nov 4, 2021. Consensus EPS estimate -0.93.
Financials — quick view
XLRN Revenue — quarterly 34.20M
XLRN Net income — quarterly -70.47M
XLRN EPS — quarterly -1.16
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2021 | Sep 1, 2021 | -0.96 | — | — | — |
| Aug 5, 2021 | Jun 1, 2021 | -0.92 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | -0.83 | — | — | — |
| Feb 25, 2021 | Dec 1, 2020 | -0.66 | — | — | — |
| Nov 5, 2020 | Sep 1, 2020 | -0.55 | — | — | — |
| Aug 6, 2020 | Jun 1, 2020 | -0.55 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 7, 2021 | Jefferies | init | — | Hold |
| Oct 4, 2021 | Raymond James | down | Strong Buy | Market Perform |
| Oct 1, 2021 | Morgan Stanley | down | Overweight | Equal-Weight |
| Oct 1, 2021 | Barclays | down | Overweight | Equal-Weight |
| Oct 1, 2021 | Cowen & Co. | down | Outperform | Market Perform |
| Sep 30, 2021 | HC Wainwright & Co. | down | Buy | Neutral |
News
Merck Scores A 'Must-Win' For Its $11.5 Billion Acceleron Buyout 
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's Inadequate Offer 
Is Merck's Planned Acquisition of Acceleron in Trouble? 
Avoro Capital Releases Presentation Detailing Why Acceleron Shareholders Should Not Tender Into Merck's Inadequate Offer 
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data 
Acceleron Pharma (XLRN) Reports Q3 Loss, Lags Revenue Estimates 
Acceleron Reports Third Quarter 2021 Financial Results 
SHAREHOLDER ALERT: WeissLaw LLP Reminds DWSN, PAE, XLRN, and FLXN Shareholders About Its Ongoing Investigations 
Merck Pushes Acceleron Buyout By Refiling For Antitrust Review 
Avoro Capital Issues Open Letter to Fellow Acceleron Pharma Shareholders
Your note
Sign in to keep a note on XLRN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DABLE HABIB J. | Chief Executive Officer | Sale | Jul 1, 2021 | 98,450 |
| HAMILL LAURA | Director | Stock Award(Grant) | Jan 28, 2021 | 474 |
| KANGO SUJAY R | Officer | Sale | Mar 1, 2021 | 19,396 |
| KEARNEY TERRENCE C | Director | Stock Award(Grant) | Jan 28, 2021 | 6,749 |
| MCCOURT THOMAS A | Director | Sale | Apr 18, 2021 | 6,044 |
| MCLAUGHLIN KEVIN F | Chief Financial Officer | Stock Award(Grant) | Jan 28, 2021 | 10,681 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Associates Inc | 8.77% | 5,365,133 | 923.34M | Sep 29, 2021 |
| Vanguard Group, Inc. (The) | 8.05% | 4,925,189 | 847.63M | Sep 29, 2021 |
| Avoro Capital Advisors LLC | 6.54% | 4,000,000 | 688.40M | Sep 29, 2021 |
| Blackrock Inc. | 6.50% | 3,972,924 | 683.74M | Sep 29, 2021 |
| Farallon Capital Management Llc | 3.54% | 2,164,663 | 372.54M | Sep 29, 2021 |
| FMR, LLC | 3.39% | 2,072,735 | 356.72M | Sep 29, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.52% | 1,543,858 | 193.74M | Jun 29, 2021 |
| Price (T.Rowe) New Horizons Fund | 2.34% | 1,432,837 | 179.81M | Jun 29, 2021 |
| Price (T.Rowe) Health Sciences Fund | 2.33% | 1,427,089 | 179.09M | Jun 29, 2021 |
| Vanguard Small-Cap Index Fund | 2.22% | 1,359,230 | 170.57M | Jun 29, 2021 |
| Vanguard Small-Cap Growth Index Fund | 1.40% | 858,419 | 107.72M | Jun 29, 2021 |
| Fidelity Select Portfolios - Biotechnology | 1.38% | 842,586 | 145.01M | Sep 29, 2021 |